Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

MANAGEMENT OF NEOVASCULAR OCULAR HISTOPLASMOSIS

Past and Present

Blinder, Kevin J., MD

doi: 10.1097/IAE.0000000000002352
Review: PDF Only

Purpose: To review the wide variety of treatment modalities available for choroidal neovascularization secondary to the presumed ocular histoplasmosis syndrome.

Methods: A literature search was performed to review the multitude of studies conducted to investigate the efficacy and safety of treatment modalities available for choroidal neovascularization secondary to the presumed ocular histoplasmosis syndrome.

Results: Each treatment modality is reviewed, with the studies summarized and presented to support or refute the method of treatment. Two case reports are presented to demonstrate the treatment regimens.

Conclusion: This is a comprehensive review of the treatment modalities available to address choroidal neovascularization secondary to the presumed ocular histoplasmosis syndrome. Investigators will continue to strive toward higher efficacy and safety with future innovations in the field.

This is a review of treatment modalities available for choroidal neovascularization secondary to the presumed ocular histoplasmosis syndrome. Two cases are presented initially. This is followed by a historical view of antiquated treatment options, ending with contemporary treatment recommendations with the various studies presented and reviewed.

The Retina Institute, St. Louis, Missouri; and Ophthalmology and Visual Sciences, Washington University, St. Louis, Missouri.

Reprint requests: Kevin J. Blinder, MD, The Retina Institute, 1600 S Brentwood Boulevard, Suite 800, St. Louis, MO 63144; e-mail: KJBlinder@gmail.com

K. J. Blinder is a consultant for Regeneron, Bausch & Lomb, Allergan, and Dorc.

The author declares no significant competing financial, professional, or personal interests that might have influenced the performance or presentation of the work described in this manuscript.

© 2018 by Ophthalmic Communications Society, Inc.